Reduced intensity VEPEMB regimen compared with standard ABVD in elderly Hodgkin lymphoma patients: results from a randomized trial on behalf of the Fondazione Italiana Linfomi (FIL)

British Journal of Haematology
Francesco ZallioAlessandro Levis

Abstract

Survival rates for elderly Hodgkin Lymphoma (HL) have not improved substantially in recent years, mainly because of a lack of prospective randomized studies, due to difficulties in enrolling patients. Between 2002 and 2006, 54 untreated HL patients, aged between 65 and 80 years and considered 'non-frail' according to a comprehensive geriatric evaluation, were enrolled into a phase III randomized trial to compare a reduced-intensity regimen (vinblastine, cyclophosphamide, procarbazine, prednisone, etoposide, mitoxantrone, bleomycin; VEPEMB) with standard ABVD (adriamycin, bleomycin, vinblastine, dacarbazine). Primary endpoint was progression-free survival (PFS). Seventeen patients were in early stage (I-IIA), while 37 were advanced stage. Median age was 72 years and median follow-up was 76 months. Five-year PFS rates were 48% vs. 70% [adjusted Hazard ratio (HR) = 2·19, 95% confidence interval (CI) = 0·94-5·10, P = 0·068] and 5-year overall survival (OS) rates were 63% vs. 77% (adjusted HR = 1·67, 95% CI = 0·69-4·03, P = 0·254) for VEPEMB compared to ABVD. Overall treatment-related mortality was 4%. World Health Organization grade 4 cardiac and lung toxicity occurred in four patients treated with ABVD versus no cases in the VEPEM...Continue Reading

References

Aug 29, 2000·Critical Reviews in Oncology/hematology·L Balducci, C Beghe
Aug 29, 2000·Critical Reviews in Oncology/hematology·L Repetto, D Comandini
Feb 15, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Colin D WeekesUNKNOWN Nebraska Lymphoma Study Group
Oct 31, 2002·British Journal of Haematology·Gail L StarkUNKNOWN Northern Region Lymphoma Group
May 20, 2003·Journal of the American Geriatrics Society·Patrizia RinaldiAntonio Cherubini
Sep 21, 1963·JAMA : the Journal of the American Medical Association·S KATZM W JAFFE
Dec 18, 2003·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A LevisUNKNOWN Intergruppo Italiano Linfomi (IIL)
Jan 24, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bruce D ChesonUNKNOWN International Harmonization Project on Lymphoma
May 10, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Martine Extermann, Arti Hurria
Mar 29, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Anas YounesRobert Chen
Nov 22, 2012·British Journal of Haematology·Gaetano CorazzelliAntonio Pinto
Dec 19, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Alison J MoskowitzCraig H Moskowitz
Jan 9, 2013·Annals of Internal Medicine·An-Wen ChanDavid Moher
Mar 20, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Boris BöllPeter Borchmann
Mar 20, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Andrew M Evens, Fangxin Hong

❮ Previous
Next ❯

Citations

Mar 4, 2018·Blood·Sean H Lim, Peter W M Johnson
Oct 11, 2017·Clinical Medicine Insights. Oncology·Pamela B Allen, Leo I Gordon
Jul 12, 2018·Current Opinion in Oncology·Sven BorchmannBoris Böll
Nov 9, 2018·British Journal of Haematology·Jemma Longley, Peter W M Johnson
Nov 9, 2018·British Journal of Haematology·Boris Böll, Helen Görgen
Mar 29, 2019·Current Oncology Reports·Pamela B Allen, Jane N Winter
Sep 3, 2019·Hematological Oncology·Emanuele CenciniMonica Bocchia
Feb 28, 2020·Leukemia & Lymphoma·Pamela B AllenChristopher Flowers
Apr 25, 2020·Current Treatment Options in Oncology·Jordan CarterAndrew M Evens
Jun 12, 2021·Journal of Cachexia, Sarcopenia and Muscle·Vittorio Ruggero ZilioliAlessandra Tucci

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.